Trial in progress: phase I study of non-viral gene-modified CAR-T cell therapy for malignant solid tumors expressing EPHB4 receptor (CARTiEr).
Saved in:
| Title: | Trial in progress: phase I study of non-viral gene-modified CAR-T cell therapy for malignant solid tumors expressing EPHB4 receptor (CARTiEr). |
|---|---|
| Authors: | Funasaka C; Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan., Naito Y; Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.; Department of General Internal Medicine, National Cancer Center Hospital East, Kashiwa, Chiba, Japan., Kubota H; Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Chiba, Japan., Ishiguro Y; Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Chiba, Japan., Fuse N; Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Chiba, Japan., Wakabayashi M; Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Chiba, Japan., Sato A; Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Chiba, Japan., Yuda J; Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.; Department of Hematology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan., Ishii G; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan., Suzuki T; Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, Kashiwa, Chiba, Japan., Takenouchi K; Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, Kashiwa, Chiba, Japan., Nakatsura T; Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, Kashiwa, Chiba, Japan., Morita K; A-SEEDS Co., Ltd., Matsumoto, Nagano, Japan., Inada Y; A-SEEDS Co., Ltd., Matsumoto, Nagano, Japan., Tanaka M; A-SEEDS Co., Ltd., Matsumoto, Nagano, Japan.; Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Nagano, Japan.; Center for Advanced Research of Gene and Cell Therapy (CARS), Shinshu University School of Medicine, Innovative Research & Liaison Organization, Matsumoto, Nagano, Japan., Nakazawa Y; A-SEEDS Co., Ltd., Matsumoto, Nagano, Japan.; Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Nagano, Japan., Yagyu S; A-SEEDS Co., Ltd., Matsumoto, Nagano, Japan.; Center for Advanced Research of Gene and Cell Therapy (CARS), Shinshu University School of Medicine, Innovative Research & Liaison Organization, Matsumoto, Nagano, Japan., Doi T; Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. |
| Source: | Frontiers in oncology [Front Oncol] 2025 Aug 06; Vol. 15, pp. 1633324. Date of Electronic Publication: 2025 Aug 06 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2025.1633324 |
